Patients with cutaneous sarcoidosis — a rare disease with no FDA-approved treatments — saw clinical and quality-of-life benefits with the investigational drug brepocitinib, according to phase 2 study results.
Sarcoidosis is a granulomatous disease that almost always affects multiple organs in the body, according to Misha Rosenbach, MD, professor of dermatology and rheumatology and director of the Sarcoidosis Clinic at the Hospital of the University of Pennsylvania. The most frequently affected organs are the lungs, followed by the skin and eyes. Some sarcoidosis cases can also involve the